Novel lappaconitine derivatives and uses thereof

A novel lapaconitine derivative stimulates osteogenesis by differentiating stem cells into osteoblasts, addressing the need for effective bone formation promotion in treating osteoporosis and fractures.

JP7595368B2Active Publication Date: 2024-12-06Q GENETICS CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022554603
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-03-09
Filing Date
2021-03-05
Publication Date
2024-12-06
Estimated Expiration
2041-03-05

AI Technical Summary

Technical Problem

Current treatments for bone diseases such as osteoporosis and fractures lack effective compounds that promote osteogenesis and bone formation.

Method used

A novel lapaconitine derivative, represented by Chemical Formula 1, and its stereoisomers, hydrates, solvates, and pharmaceutically acceptable salts, which are synthesized through specific chemical reactions, promote osteogenesis by inducing the differentiation of stem cells into osteoblasts and increasing bone density.

Benefits of technology

The lapaconitine derivative enhances bone formation and density, effectively treating bone-related diseases like osteoporosis and fractures by increasing calcium and mineral production, and inducing key osteogenic markers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595368000013
    Figure 0007595368000013
  • Figure 0007595368000014
    Figure 0007595368000014
  • Figure 0007595368000015
    Figure 0007595368000015
Patent Text Reader

Abstract

The present invention relates to a novel lappaconitine derivative, a method for producing the same, and a pharmaceutical use of the same utilizing its osteogenic activity. The lappaconitine derivative induces differentiation of stem cells into osteoblasts, increases bone mineral density when administered to an osteoporosis animal model, and induces bone formation in an osteofracture animal model. Therefore, the lappaconitine derivative can be useful not only for preventing, ameliorating, or treating bone-related diseases such as osteoporosis, but also for treating non-pathological fractures caused by physical trauma.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel lappaconitine derivative belonging to the diterpenoid alkaloid series, a method for producing the same, and a pharmaceutical use thereof utilizing its bone formation promoting activity. [Background technology]

[0002] Aconitine, one of the components of the traditional Chinese medicine Aconiti Lateralis Radix, is a highly toxic compound belonging to the alkaloid series. However, just as the toxicity of Aconiti Lateralis Radix is ​​reduced when it is boiled, when this compound is directly heated, it is converted into less toxic compounds such as benzoylaconine and aconine through diacetylation and dibenzoylation. Due to this principle, Aconiti Lateralis Radix (processed or refined) that has been heat-treated to reduce its toxicity has been used as a medicine to reduce inflammation and pain in patients with neuralgia (Xu et al., J Ethnopharmacol 2006).

[0003] In addition, hundreds of alkaloid compounds, such as dioxyaconitine, mesaconitine, hypaconitine, and lappaconitine, which belong to the diterpenoid alkaloid series and have similar chemical structures to aconitine, have been studied through semi-synthesis and structural confirmation, and their physiological activities are being revealed one after another (Turabekova et al., Environ Toxicol Pharmacol. 2008). For example, Shaanxi University of Science and Technology published results showing that removing the 2-acetaminobenzoyl group at the 4th carbon position of lappaconitine and attaching various cinnamic derivatives showed anti-cancer activity, and the same university synthesized various compounds by changing the functional groups at the 4th, 8th, and 9th positions (Liang Cheng et al., CN107540680A, published on January 5, 2018). Dr. Vladimirovich of Russia also confirmed the inflammatory effects of derivatives in which various aromatic compounds were attached to the 4-position of lappaconitine (SV Vladimirovich, WO2017 / 209653 A1). Among many alkaloid compounds, lappaconitine is known to have various efficacies such as antiarrhythmic, anti-inflammatory, antioxidant, anticancer and anti-epileptic (Wang et al., Chem Pharm Bull. 2009). While studying the new pharmacological activity of lappaconitine, the present inventors hydrolyzed lappaconitine to produce a compound with a new structure, and found that the new compound promotes osteogenesis, thus completing the present invention. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] WO2017 / 209653 A1 Summary of the Invention [Problem to be solved by the invention]

[0005] An object of the present invention is to provide a novel lappaconitine derivative having a function of promoting bone formation and a function of treating osteoporosis, a method for producing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing, ameliorating or treating bone diseases. [Means for solving the problem]

[0006] In order to achieve the above object, one aspect of the present invention provides a compound represented by the following chemical formula 1, a stereoisomer thereof, a hydrate thereof, a solvate thereof, or a pharma- ceutically acceptable salt thereof.

[0007] [ka]

[0008] According to one embodiment of the present invention, in the formula 1, R1 and R2 may each independently be selected from the group consisting of hydrogen, C1-C6 alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylaryl, dioxolanylaryl, carboalkoxyalkyl, methyl, ethyl, isopropyl, t-butyl, and phenyl, wherein "alk-" or "alkyl" is preferably C1-C3 alkyl, either branched or linear, and wherein the carbon chain may be optionally interrupted by an ether (-0-) bond.

[0009] According to one embodiment of the present invention, the compound of formula 1 is (2aR,2a1S,3S,4aS,8S,11S,11bS,12S)-6-ethyl-4a,8-dihydroxy-3,11-dimethoxy-tetradecahydro-8,11a,5-(epiethan[1,1,2]tolyl)cyclopenta[7,1]indeno[5,4-b]azocine-1,2-dione (chemical formula 2).

[0010] [ka]

[0011] In the present invention, the compound of Chemical Formula 1 includes not only the compound represented by Chemical Formula 1, its pharma- ceutically acceptable salts, but also their hydrates, solvates, stereoisomers and radioactive derivatives.

[0012] The term "pharmaceutical acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals without causing excessive toxicity, irritation, allergic reactions, etc., within the scope of pure medical judgment, and does not adversely affect the biological activity and physicochemical properties of the parent compound. The pharmaceutical acceptable salt is well known in the art. For example, it is described in detail in the literature (SM Berge, et al., J. Pharmaceutical Sciences, 66, 1, 1977). The salt may be prepared in the same reaction system during the final separation and purification of the compound of the present invention, or may be prepared separately by reacting with an inorganic base or an organic base. Suitable addition salt forms include, for example, ammonium salts, alkali metal salts and alkaline earth metal salts (including calcium salts) such as lithium, sodium, potassium, magnesium, calcium, etc. salts, salts with organic bases, for example salts with primary, secondary and tertiary aliphatic and aromatic amines, such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, benzathine, N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as arginine, lysine, etc.

[0013] In the present invention, the hydrate or solvate of the compound of Chemical Formula 1 may be prepared by a conventional method, for example, by dissolving the base compound of Chemical Formula 1 in a solvent such as water, methanol, ethanol, acetone, 1,4-dioxane, etc., adding a free acid or a free base, and then crystallizing or recrystallizing the solution.

[0014] The compounds of formula 1 may have one or more asymmetric centers, and in the case of such compounds, enantiomers or partial stereoisomers may exist. Thus, the compounds of the present invention include each isomer or a mixture of these isomers. Different isomers may be separated or resolved by conventional methods, or any isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric synthesis. The compounds of the present invention also include radioactive derivatives of the compounds represented by the above formula, and these radioactive compounds are useful in the field of biological research.

[0015] In the present invention, the compound of Formula 1 may be prepared by a method including the following steps:

[0016] (a) reacting lappaconitine with an oxidizing agent; and (b) reacting the result of (a) with an organic solvent in the presence of a base.

[0017] According to one embodiment of the present invention, the lappaconitine in (a) may be lappaconitine hydrobromide, and in this case, step (a) may further include a step of removing hydrogen bromide before reacting lappaconitine with an oxidizing agent. For example, the step of removing hydrogen bromide from lappaconitine hydrobromide may be carried out using dichloromethane (CH2Cl2) in the presence of a base as shown in the following reaction scheme 1.

[0018] [ka]

[0019] Lappaconitine may then be oxidized by reacting with an oxidizing agent to produce a lappaconitine derivative (LAD) as shown in Scheme 2 below. The oxidizing agent may be selected from the group consisting of iodobenzene diacetate (PhI(OAc)2 or lead(II) acetate (Pb(CH3CO2)2), lead(II) acetate (Pb(CH3CO2)4), ozone, and HIO4 dissolved in dimethylformamide (DMF).

[0020] [ka]

[0021] In the present invention, the synthesized lappaconitine derivative (LAD) may react with an organic solvent in the presence of a base to produce the compound of Formula 1. The base may be selected from the group consisting of sodium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, and potassium hydroxide, and the organic solvent may be an aliphatic alcohol or an alkoxy alcohol.

[0022] The aliphatic alcohol refers to an alcohol represented by the general formula CH3(CH2)nOH (n is 0 or a positive integer), and the alkoxy alcohol refers to an alcohol represented by the general formula CH3(CH2)nO(CH2)nCH3 (n is independently 0 or a positive integer). For example, the aliphatic alcohol may be specifically methanol, ethanol, n-propanol, isopropanol, n-butanol, etc., and the alkoxy alcohol may be methoxymethanol, methoxyethanol, ethoxyethanol, etc.

[0023] For example, the lappaconitine derivative (LAD) may be reacted with ethanol in the presence of sodium hydroxide to produce a compound of Formula 1 (QG3030) as shown in Reaction Scheme 3 below.

[0024] [ka]

[0025] In the present invention, the compound of Chemical Formula 1 synthesized by the above method may be separated by a general separation and purification process, for example, dilution and washing with an organic solvent, followed by concentrating the organic layer under reduced pressure, and if necessary, may be purified by column chromatography and recrystallization using various solvents.

[0026] The present inventors have been studying new pharmacological activities of lappaconitine, which has anti-inflammatory, antioxidant, anti-cancer and other efficacious properties, and have synthesized a novel compound of Chemical Formula 1 by hydrolyzing lappaconitine, and have confirmed that this compound has bone formation promoting activity.

[0027] Therefore, another aspect of the present invention provides a pharmaceutical composition for preventing or treating a bone-related disease, comprising the compound represented by Formula 1 or a pharma- ceutically acceptable salt thereof as an active ingredient.

[0028] In the pharmaceutical composition, the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof includes a hydrate, a solvate, a stereoisomer and a radioactive derivative thereof.

[0029] According to one embodiment of the present invention, the compound of formula 1 can promote differentiation of stem cells into osteoblasts and increase the expression of bone formation markers selected from the group consisting of RUNX2 (runt-related transcription factor 2), BMP2 (bone morphogenetic protein 2) and osteocalcin, thereby promoting bone formation. As the stem cells, mesenchymal stem cells, hematopoietic stem cells, adipose stem cells, bone marrow stem cells, etc. may be used.

[0030] In the present invention, the bone disease may be selected from the group consisting of osteoporosis, bone fracture, rheumatoid arthritis, periodontitis, osteomalacia, osteopenia, bone atrophy, osteoarthritis, bone defect, osteolysis and osteonecrosis, and is preferably bone fracture and osteoporosis.

[0031] The term "fracture" as used herein means a condition in which a bone supporting the body is broken due to a traffic accident, a fall, an industrial accident, and other physical stimuli.

[0032] The term "osteoporosis" as used herein refers to a condition in which the minerals (especially calcium) and matrix that constitute bone are reduced, causing the microstructure of bone tissue to degenerate, resulting in a persistent increase in the risk of fracture. Types of osteoporosis include primary osteoporosis, such as postmenopausal osteoporosis and senile osteoporosis, and secondary osteoporosis caused by diseases, drugs, alcohol, smoking, etc. that affect bone formation and reduction.

[0033] The pharmaceutical composition of the present invention may further contain suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceuticals, in addition to containing the compound of Formula 1 as an active ingredient. Carriers, excipients and diluents that may be contained in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphite, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

[0034] When the pharmaceutical composition of the present invention is formulated, it is prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, or surfactant. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations are prepared by mixing the composition of the present invention with at least one or more sub-excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, liquids, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, flavorings, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent or suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, or the like may be used.

[0035] The pharmaceutical composition of the present invention may be administered orally or parenterally, and the preferred dosage of the composition of the present invention may vary depending on the condition and weight of the patient, the severity of the disease, the drug form, the administration route and period, and may be appropriately selected by those skilled in the art. For example, the dosage of the compound of Formula 1 may vary depending on the age, weight, sex, administration form, health condition and severity of the disease of the patient, and may be generally administered at 0.01 mg to 5000 mg per day for an adult patient weighing 70 kg. The dosage may be administered once or in several divided doses per day, and the dosage does not limit the scope of the present invention in any way.

[0036] The present invention also provides a method for treating a bone disease, comprising administering the pharmaceutical composition to an individual in need of treatment. The type of bone disease and the dosage of the pharmaceutical composition are the same as those described in the pharmaceutical composition for preventing or treating a bone disease.

[0037] In the present invention, when the pharmaceutical composition for preventing or treating bone diseases is orally administered, the pharmaceutical composition for oral administration may be a solid preparation, semi-solid preparation or liquid preparation for oral administration. Examples of solid preparations for oral administration include, but are not limited to, tablets, pills, hard or soft capsules, powders, fine granules, granules, powders for reconstitution into solutions or suspensions, lozenges, wafers, oral strips, dragees and chewable gums. Examples of liquid preparations for oral administration include solutions, suspensions, emulsions, syrups, elixirs, spirits, aromatic perfumes, lemonades, extracts, precipitates, tinctures and medicinal oils.

[0038] In the present invention, when the pharmaceutical composition for preventing or treating bone diseases is used as an injection, it may be directly injected into the site of bone disease, and when formulated as an injection, it may contain a non-toxic buffer solution that is isotonic with blood as a diluent, such as a phosphate buffer solution at pH 7.4. The injection may contain other diluents or additives in addition to the buffer solution.

[0039] According to one embodiment of the present invention, the pharmaceutical composition may be mixed with an excipient such as a collagen sponge and then implanted at the site of a fracture to treat an individual.

[0040] Another aspect of the present invention provides a food composition for preventing or improving bone diseases, comprising the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof as an active ingredient.

[0041] In the food composition, the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof includes a hydrate, a solvate, and a stereoisomer thereof.

[0042] Since the food composition uses the same ingredients as the pharmaceutical composition for preventing or treating bone diseases, the overlapping contents therebetween will be omitted to avoid excessive description in the specification.

[0043] In the present invention, the food composition may be provided in the form of powder, granule, tablet, capsule, syrup, drink or pill, and may be used together with other foods or food additives in addition to the compound represented by Chemical Formula 1 as an active ingredient, and may be appropriately used in a conventional manner. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use, such as prevention, health or therapeutic treatment.

[0044] The effective dose of the active ingredient contained in the food composition can be used in accordance with the effective dose of the pharmaceutical composition, but in the case of long-term intake for the purposes of health and hygiene or health regulation, it may be below the above range, and it is clear that the active ingredient can also be used in an amount greater than the above range since there is no problem in terms of safety.

[0045] The food composition includes ingredients that are usually added during food production, such as proteins, carbohydrates, fats, nutrients, seasonings, and flavorings. Examples of the carbohydrates mentioned above include monosaccharides, such as glucose, fructose, disaccharides, such as maltose, sucrose, oligosaccharides, and polysaccharides, such as dextrin, cyclodextrin, and other common sugars, and sugar alcohols, such as xylitol, sorbitol, and erythritol. Natural flavorings and synthetic flavorings may be used as flavorings. For example, when the food composition of the present invention is produced as a drink, it may further include citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and the like, in addition to the active ingredient of the present invention.

[0046] Yet another aspect of the present invention provides a composition for inducing osteoblast differentiation in vitro using the compound represented by Chemical Formula 1.

[0047] According to one embodiment of the present invention, treatment of mesenchymal stem cells with the compound represented by Chemical Formula 1 increases calcium and mineral production, thereby promoting differentiation of stem cells into osteoblasts. Effect of the Invention

[0048] The lappaconitine derivative of the present invention induces differentiation of stem cells into osteoblasts, increases bone density when administered to an animal model of osteoporosis, and promotes bone formation when injected into the fracture site of an animal model of fracture, thereby promoting recovery from fracture trauma and inducing bone formation, and therefore may be usefully used for the prevention, amelioration or treatment of bone-related diseases such as fractures and osteoporosis. [Brief description of the drawings]

[0049] [Figure 1] FIG. 1 shows the structure of a lappaconitine derivative (QG3030) according to an example of the present invention. [Figure 2a] FIG. 2a shows the levels of calcium (alizarin red) and mineral production (Von Kosa) after treatment of mesenchymal stem cells with a lappaconitine derivative (QG3030). [Figure 2b] FIG. 2b is a graphical representation of the degree of staining in FIG. 2a. [Figure 3a] FIG. 3a shows the change in RUNX2 expression after treating mesenchymal stem cells with various concentrations of a lappaconitine derivative (QG3030) for a certain period of time. [Figure 3b] FIG. 3b shows the change in BMP-2 expression after mesenchymal stem cells were treated with various concentrations of a lappaconitine derivative (QG3030) for a certain period of time. [Figure 4a] FIG. 4a shows the change in osteocalcin expression observed by fluorescence microscopy after mesenchymal stem cells were treated with various concentrations of a lappaconitine derivative (QG3030) for a certain period of time. [Figure 4b] FIG. 4b is a graphical representation of the fluorescence levels of FIG. 4a. [Figure 5a] FIG. 5a shows the phosphorylation levels of various kinases after treating mesenchymal stem cells with a lappaconitine derivative (QG3030). [Figure 5b] FIG. 5b is a graphical representation of the phosphorylation levels of FIG. 5a. [Figure 6]FIG. 6 shows calcium levels after mesenchymal stem cells were treated with a lappaconitine derivative (QG3030) and various kinase inhibitors. [Figure 7a] FIG. 7a shows the level of phosphorylated ERK (pERK) after treating mesenchymal stem cells with a lappaconitine derivative (QG3030) for 0 to 24 hours. [Figure 7b] FIG. 7b shows the level of phosphorylated ERK (pERK) after mesenchymal stem cells were treated with a lappaconitine derivative (QG3030) for 7 days. [Figure 7c] FIG. 7c shows the level of phosphorylated ERK (pERK) after mesenchymal stem cells were treated with a lappaconitine derivative (QG3030) for 14 days. [Figure 8a] FIG. 8a shows the change in RUNX2 expression confirmed by fluorescence microscopy after mesenchymal stem cells were treated with both a lappaconitine derivative (QG3030) and an ERK inhibitor (PD98059). [Figure 8b] FIG. 8b is a graphical representation of the fluorescence levels of FIG. 8a. [Figure 8c] FIG. 8c shows the level of phosphorylated ERK (pERK) after treating mesenchymal stem cells with both a lappaconitine derivative (QG3030) and an ERK inhibitor (PD98059). [Figure 9a] FIG. 9a shows the schedule of administration of a lappaconitine derivative (QG3030) to an osteoporosis animal model and the types of experimental groups. [Figure 9b] FIG. 9b shows the cross section of the femur after administration of a lappaconitine derivative (QG3030) to an osteoporosis animal model. [Figure 9c] FIG. 9c shows the bone density of the femur after administration of a lappaconitine derivative (QG3030) to an osteoporosis animal model. [Figure 10a] FIG. 10a shows the bone formation level after administration of a lappaconitine derivative (QG3030) to an osteoporosis animal model. [Figure 10b]FIG. 10b shows the expression level of RUNX2 after administration of a lappaconitine derivative (QG3030) to an osteoporosis animal model. [Figure 11] FIG. 11 is a schematic diagram showing the method of administering a lappaconitine derivative (QG3030) to an animal model of fracture. [Figure 12a] FIG. 12a shows the results of observing the cross section of a rat ilium bone after administration of a lappaconitine derivative (QG3030) to an animal model of fracture. [Figure 12b] FIG. 12b shows the results of confirming the degree of bone formation in rat ilium after administration of a lappaconitine derivative (QG3030) to an animal fracture model. [Figure 13] FIG. 13 shows the results of confirming the bone formation level (A) and collagen expression level (B) after administration of a lappaconitine derivative (QG3030) to an animal model of fracture. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] Hereinafter, one or more specific examples will be described in more detail through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0051] Manufacturing example: Manufacturing of QG3030 1-1. Production of Lappaconitine Lappaconitine hydrogen bromide (10.08 g, 0.017 mol) was added to dichloromethane (500 ml) and sodium hydroxide solution (NaOH 10 g + water 100 g), and the aqueous and organic layers were separated using a separatory funnel. The separated organic layer was washed several times with water, dried over anhydrous magnesium sulfate, and then distilled to obtain the desired lappaconitine in 89% yield (8.90 g).

[0052] 1H-NMR (CDCl3, 400MHz) δ10.98 (s, 1H), 8.60 (d, J=8.4Hz, 1H), 7.86-7.83 (m, 1H), 7 .42(t, 1H), 6.95(t, 1H), 3.52-3.37(m, 2H), 3.36-3.35(m, 2H), 3.36(s, J=7.1Hz, 3H), 3.22(s, 3H), 3.13(s, 3H), 3.11-3.09(m, 2H), 2.60-2.46(m, 10H), 2.15(s, 3H ), 2.14-1.73(m, 6H), 1.74-1.68(m, 1H), 1.74-1.70(m, 1H), 1.06(t, J=6.8Hz, 3H);

[0053] 13 C-NMR (CDCl3, 100MHz) δ169.02, 167.39, 141.6, 134.34, 131.07, 122.31, 120.19, 115.76, 90.10, 84.62, 84.13, 82.89, 78.57, 75.5 6. 61.48, 57.89, 56.52, 56.10, 55.50, 50.85, 49.86, 48.97, 48.51, 47.61, 44.76, 36.28, 31.83, 26.77, 26.20, 25.53, 24.12, 13.53;

[0054] HRMS(ES + ):m / z calculated for C 32 H 44 N2O8:585.3098[M+H] + . Found 585.3176.

[0055] 1-2.Manufacturing of lanolin derivative (LAD) Lappaconitine (8.9 g, 0.015 mol) was slowly added to a solution of iodobenzene diacetate (PhI(OAc)2 (14.07 g, 0.044 mol) dissolved in dimethylformamide (DMF, 150 ml) and stirred for 10 minutes. When the reaction was completed, the solution was diluted with ethyl acetate (EA) and extracted with a saturated aqueous sodium bicarbonate (NaHCO3) solution. The organic layer was washed several times with water to remove dimethylformamide, then dried over anhydrous magnesium sulfate and distilled under reduced pressure. The crude product was separated through column chromatography (diethyl ether:ethyl acetate:hexane=3:2:5) to obtain the desired lappaconitine derivative. The compound (LAD) {(3S,6S,7S,9S,11S,16S)-1-ethyl-6,9,11-trimethoxy-8,13-dioxododecahydro-2H-3,6a,14-(epiethan[1,1,2]triyl)-7,10-methanocyclodeca[b]azocin-3(4H)-yl 2-acetaminobenzoate} was obtained in a yield of 25.7% (2.3 g).

[0056] 1 H-NMR (CDCl3, 400MHz) δ10.99(s, 1H), 8.62(d, J=8.4Hz, 1H), 7.89(d, J=9.6Hz, 1H) 7.47-7.43(m, 1H), 7.01-6.99(m, 1H), 3.88- 3.64(m, 4H), 3.65(s, 3H), 3.41(s, 3H), 3.18(s, 3H), 2.90-2.25(5, 4H), 2.20(s, 3H), 2.19-1.80(m, 4H), 1.15(t, J=7.0Hz, 3H);

[0057] 13C-NMR (CDCl3, 100MHz) δ211.85, 204.31, 169.10, 167.40, 162.18, 143.74, 141.74, 134.61, 131.07, 122.41, 120.30, 115.45, 86.92, 82 .75, 81.45, 78.21, 76.28, 60.73, 58.17, 57.37, 54.35, 52.98, 50.19, 48.78, 46.06, 45.92, 38.41, 32.06, 25.56, 25.39, 25.36, 12.72;

[0058] HRMS(ES + ):m / z calculated for C 32 H 42 N2O8:583.3018[M+H] + .

[0059] Found 583.2941.

[0060] 1-3. Manufacturing QG3030 from LAD LAD (2.3 g), sodium hydroxide solution (NaOH 0.7 g + water 5.1 g) and ethanol (51 ml) were added to a 100 ml three-necked round-bottom flask and refluxed for 1 hour. After completion of the reaction, ethanol was distilled and column chromatogram was performed with ethyl acetate to obtain the final compound QG3030 {(2aR,2a1S,3S,4aS,8S,11S,11bS,12S)-6-ethyl-4a,8-dihydroxy-3,11-dimethoxy-tetradecahydro-8,11a,5-(epiethan[1,1,2]triyl)cyclopenta[7,1]indeno[5,4-b]azocine-1,2-dione} in 62.5% (1.4375 g) yield.

[0061] 1H-NMR (DMSO-d6, 400MHz) δ8.88(s, 1H), 4.65(s, 1H), 4.35(s, 1H), 4.27-4.20(9m, 1H), 4.10-4.00(m, 1H), 3.60(s , 1H), 3.35(s, 3H), 3.20(s, 3H), 3.10-2.99(m, 1H), 2.85-2.19(m, 6H), 1.99-1.50(m, 7H), 1.05(t, J=7.0Hz, 3H);

[0062] 13 C-NMR (CDCl3, 100MHz) δ201.20, 149.88, 148.78, 83.25, 79.92, 79.50, 67.87, 62.74, 60.20, 58.10, 53.23, 49.55, 48.86, 47.88, 46.92, 42.39, 38.43, 13.56;

[0063] HRMS(ES + ):m / z calculated for C 32 H 31 NO6: 406.2151 [M+H] + .

[0064] Found 406.2242;X-ray structure.

[0065] 1-4.Confirmation of the structure of QG3030 The QG3030 obtained in Preparation Example 1-4 was recrystallized in water to obtain suitable crystals by X-ray diffraction, which were then used to confirm the X-ray structure (X-ray Diffractometer, R-AXIS RAPID). The results are shown in FIG. 1 and Table 1.

[0066] [Table 1] EXAMPLES

[0067] Experimental Example 1: Confirmation of efficacy of QG3030 (in vitro) 1-1. Confirmation of bone cell differentiation ability of QG3030 in MSCs Osteoblasts, which are involved in bone formation, are generated by differentiation from mesenchymal stem cells (MSCs) in response to external stimuli and various transcription factors related to signal transduction (Garg et al., Orthop Surg. 2017). Therefore, we tested whether QG3030 could induce osteoblast differentiation from human MSCs.

[0068] Normal human MSCs were purchased from ATCC in the United States and cultured in MSC-specific medium (Gibco). The cultured cells were isolated with trypsin, centrifuged, and then dispensed into 24-well plates at a concentration of 3 x 104 / well. The next day, the MSC culture medium was replaced with experimental medium DMEM medium (DMEM / 10% FBS / penicillin / streptomycin), and the cells were treated with QG3030 alone (0.1 μM) or positive control OIM (osteogenesis-inducing medium; StemPro Osteogenesis Differentiation Kit, ThermoFisher Scientific Inc.). The cell culture medium was then replaced with fresh DMEM medium every day, and the cells were cultured for 3 weeks with QG3030 or OIM. After the end of the culture, the cells were stained with Alizarin Red to detect calcium and Von Kossa to detect mineral formation.

[0069] The staining results confirmed that QG3030 induced calcium and mineral production in human MSCs, similar to the osteoblast differentiation positive control OIM (Figures 2a and 2b). This result indicates that QG3030 can differentiate MSCs into osteoblasts at the cellular level.

[0070] 1-2. Confirmation of changes in RUNX2 and BMP2 expression in MSCs RUNX2 (runt-related transcription factor 2; core-binding factor alpha, Cbfa1) is the most important transcription factor for bone formation, and is known to be involved in osteoblast differentiation, matrix synthesis, and mineralization during bone formation (Bruderer M, et al., Eur Cell Mater. 2014). RUNX2 itself may also be regulated by BMP (bone morphogenetic protein), a type of cytokine (Sun J, et al., Mol Med Rep. 2015). Therefore, we confirmed whether QG3030 induces the expression of specific bone formation-related factors to induce osteogenesis.

[0071] MSCs were dispensed into 24-well plates at a concentration of 3 x 104 / well and cultured for 24 hours, and from the next day, they were treated with QG3030 at different concentrations (0.001 μM, 0.01 μM, and 0.1 μM) once a day for 7 and 14 days. After the experiment, MSCs were stained with RUNX2 and BMP-2 antibodies and observed under a fluorescent microscope.

[0072] As a result, it was confirmed that QG3030 strongly induced the expression of RUNX2 and BMP-2 even at low concentrations (0.001 μM = 1 nM), and this tendency became stronger as the concentration increased (Figures 3a and 3b). These results indicate at the molecular level that QG3030 can induce osteoblast differentiation in human MSCs and participate in bone formation.

[0073] 1-3. Confirmation of changes in osteocalcin expression in MSCs Osteocalcin is expressed only in osteoblasts (Leee et al., Cell 2007) and is used as a useful biomarker for bone formation (Bharadwaj et al., Osteoporosis International., 2009). Therefore, we confirmed the effect of QG3030 on the expression of osteocalcin, an osteoblast-specific marker.

[0074] After performing the same experiment as in Experimental Example 1-3, MSCs were stained with osteocalcin antibody and observed under a fluorescent microscope. As a result, QG3030 strongly induced osteocalcin expression even at a low concentration (0.001 μM) after 7 days of treatment, which was at a similar level to the positive control OIM-treated group (Figures 4a and 4b).

[0075] 1-4. Confirmation of differentiation mechanism of MSCs into osteoblasts To investigate the mechanism by which QG3030 induces MSCs to differentiate into osteoblasts, the related signal transduction was investigated.

[0076] MSCs cultured in experimental DMEM culture medium were treated with QG3030 (1 μM) or a control compound (DMSO) and cultured for 24 hours. After the cells were harvested, the experiment was performed according to the method specified in the phosphokinase antibody array kit (R&D Systems), which contains antibodies that specifically recognize the phosphorylated forms of 43 types of kinases. The samples were then analyzed using the ImageJ (NIH, USA) program.

[0077] The analysis confirmed that QG3030 strongly increased the phosphorylation of signaling molecules such as ERK, Akt, and WNK1 compared to the control group DMSO (Figures 5a and 5b).

[0078] 1-5. Confirmation of differentiation mechanism of MSCs into osteoblasts To further investigate the mechanism by which QG3030 induces the differentiation of MSCs into osteoblasts, experiments were performed using kinase inhibitors.

[0079] After culturing the MSCs, they were treated with a kinase inhibitor (1 μM) and QG3030 (1 μM) simultaneously, and the next day, the medium was replaced and the cells were treated with the kinase inhibitor and QG3030 simultaneously again. This process was repeated for 3 weeks, and the MSCs were stained with Alizarin Red.

[0080] As a result, it was confirmed that the osteoblast differentiation ability of QG3030 was suppressed in the experimental group treated with an inhibitor of ERK, P38, or Akt, compared with the group treated with QG3030 alone (Figure 6). This result indicates that QG3030 is involved in the osteoblast differentiation of MSCs by activating the signal transduction of these enzymes.

[0081] 1-6. Confirmation of the effect on ERK phosphorylation in MSCs Previous studies have shown that MAP-kinase signaling, including ERK and p38, plays an important role in osteoblast differentiation (Greenblatt et al., MB, Annu Rev Cell Dev Biol. 2013). Consistent with previous studies, the results of Experimental Examples 1-5 indicate that QG3030 may induce osteoblast differentiation through ERK and p38 MAP-kinase (Figure 6). Furthermore, the results of Experimental Examples 1-4 indicate that QG3030 may induce osteoblast differentiation through phosphorylation of ERK rather than p38 (Figures 5a and 5b). Therefore, the phosphorylated ERK level was examined over time after treatment of MSCs with QG3030.

[0082] As a result, it was confirmed that the level of phosphorylated ERK (pERK) was significantly increased within 30 minutes of QG3030 treatment, and specifically, the level of phosphorylated ERK (pERK) was also increased 24 hours after QG3030 treatment (Figure 7a).

[0083] To confirm that QG3030 induces ERK phosphorylation for a long period of time, MSCs were treated with QG3030 at various concentrations (0.001, 0.01, and 0.1 μM) and the levels of phosphorylated ERK (pERK) were measured after 7 and 14 days. As a result, the levels of phosphorylated ERK (pERK) were significantly increased in all experimental groups treated with QG3030, and even at low concentrations, the levels of phosphorylated ERK (pERK) were increased more than in the positive control group, OIM. This tendency continued for 14 days after QG3030 treatment, confirming that QG3030 can increase ERK phosphorylation for a long period of time (Figures 7b and 7c).

[0084] These results suggest that long-term activation of the ERK signaling pathway by QG3030 may be the core mechanism underlying the osteoblast differentiation ability of QG3030.

[0085] 1-7. Confirmation of the effect of ERK inhibitors on the increase in RUNX2 expression by QG3030 ERK can induce phosphorylation of RUNX2 to increase its transcriptional activity and increase the amount of RUNX2 protein by participating in its stability (Greenblatt et al., MB, Annu Rev Cell Dev Biol. 2013). Therefore, the increase in ERK phosphorylation by QG3030 may induce RUNX2 expression and participate in osteoblast differentiation of MSCs. To prove this, we treated MSCs with QG3030 (0.1 μM) and PD98059 (50 μM), an ERK inhibitor, and then confirmed the expression level of RUNX2.

[0086] The results showed that RUNX2 expression was significantly increased within 12 hours of QG3030 treatment, but that it was significantly decreased when treated with the ERK inhibitor PD98059. This trend was also observed when QG3030 was treated for 24 hours (Figures 8a and 8b).

[0087] Also, as expected, QG3030 treatment increased the phosphorylation level of ERK in MSCs, which was suppressed by PD98059 treatment (Fig. 8c).

[0088] The above results indicate that induction of ERK activation by QG3030 is the major mechanism of its osteogenic activity.

[0089] Experimental Example 2: Efficacy of QG3030 (in vivo) 2-1. Confirmation of therapeutic potential of QG3030 using an osteoporosis animal model The therapeutic ability of QG3030 for osteoporosis was confirmed in an ovariectomized (OVX) mouse model, which is commonly used as an animal model for osteoporosis.

[0090] As positive controls, Forteo (Eli Lilly), a parathyroid hormone (PTH) drug used to treat osteoporosis through its bone formation promoting mechanism, and Fosamax (Merck), a bone resorption inhibitor, an alendronate drug, were administered subcutaneously. Water (H20) and QG3030 were orally administered at a concentration of 5 or 30 mg / kg in the negative control groups (Figure 9a). After daily drug administration for 10 weeks, bone mineral density (BMD) was measured.

[0091] As a result of the measurements, bone mineral density was significantly increased in the QG3030-treated group compared to the negative control group, indicating the therapeutic effect of osteoporosis. The effect of QG3030 was similar to that of Fosamax and significantly superior to that of Forteo (Figures 9b and 9c).

[0092] Furthermore, tissue staining revealed that QG3030 induced bone formation in the femurs of ovariectomized mice (Fig. 10a), and it was confirmed that the expression of RUNX2, a transcription factor involved in bone generation, was significantly increased (Fig. 10b). The experimental results are summarized in Table 2 below. In Table 2, BMD means bone mineral density, TV means total volume, BV means bone volume, Tb.Th means trabecular thickness, and Tb.N means trabecular number.

[0093] [Table 2]

[0094] 2-2. Confirmation of the therapeutic potential of QG3030 using animal models of fractures A bone defect was induced in the ilium of a Sprage Dawley (SD) rat through drilling with a diameter of 2 mm, and QG3030 (6, 30, and 150 μg / 10 μl) mixed with a vehicle (collagen sponge, CollaCote®) was transplanted into the bone defect site to evaluate the bone regeneration efficacy (FIG. 11). At this time, the positive control group was treated with BMP2 (bone morphogenic protein-2), and the negative control group was treated with DMSO (Table 3).

[0095] [Table 3]

[0096] Four weeks after implantation, micro-CT image interpretation showed that QG3030 exhibited similar levels of bone regeneration ability as BMP2 at all concentrations (Figure 12a).

[0097] To statistically quantify the bone regeneration ability of QG3030, the degree of bone formation was visualized in 3D images, and then ROIs (regions of interest) were set and analyzed using the following parameters: bone volume / total volume (BV / TV, %), trabecular thickness (Tb.Th, mm), trabecular number (Tb.N, 1 / mm), and trabecular separation (Tb.Sp, mm).

[0098] As a result, it was found that the bone volume ratio (BV / TV), an indicator of bone formation, increased to the same level in the BMP2-treated group (positive control group) and the QG3030-treated groups (low, medium, and high concentrations) compared to the negative control group treated with DMSO (Figure 12b).

[0099] In addition, the analysis of bone thickness Tb.Th, bone tissue number Tb.N, and bone tissue distance Tb.Sp to evaluate the bone quality of the formed bone tissue confirmed that the BMP2 treatment group (positive control group) and the QG3030 treatment groups (low, medium, and high concentrations) formed statistically significantly better quality bone tissue than the DMSO treatment group in terms of Tb.N and Tb.Sp except for Tb.Th (Figure 12b). An interesting point is the fact that QG3030 generates better quality bone compared to BMP2, even though the statistical significance is not large. The statistical significance index is *<0.05; **<0.01, ***<0.001.

[0100] To prove bone regeneration by QG3030 at the tissue level, tissue staining for cells (H&E, hematoxylin & eosin), collagen (Masson's trichrome), type I collagen, and osteocalcin was performed. As a result, it was confirmed that the above markers were expressed in the bone defect site (shown by solid lines) treated with QG3030 (low, medium, and high concentrations), and the effect was similar to that of BMP2 (Figure 13).

[0101] The bone regeneration results of this experiment prove that QG303O has excellent bone regeneration ability comparable to that of BMP2.

[0102] From the above results, it was confirmed that the QG3030 compound of the present invention can induce calcium and mineral production in MSCs, increase the expression of RUNX2, BMP-2 and osteocalcin, and induce ERK activation to induce differentiation into osteoblasts. In addition, since the compound increases bone density when administered to an osteoporosis animal model and induces bone formation in a fracture animal model, the QG3030 compound may be usefully used for treating bone-related diseases such as osteoporosis as well as non-pathological fractures caused by physical trauma.

[0103] Formulation examples Meanwhile, the novel compound QG3030 according to the present invention can be formulated in various forms according to the purpose. The following are examples of methods for formulating compositions containing the novel compound QG3030 according to the present invention as an active ingredient, but the present invention is not limited thereto.

[0104] 1. Tablets (direct compression) 5.0 mg of the active ingredient was sieved, mixed with 14.1 mg of lactose, 0.8 mg of crospovidone USNF and 0.1 mg of magnesium stearate and compressed into tablets.

[0105] 2. Tablets (wet assembly) 5.0mg of active ingredient was sieved, then mixed with 16.0mg lactose and 4.0mg starch. 0.3mg polysorbate 80 was dissolved in pure water, then the solution was added to the mixture in an appropriate amount to form fine particles. After drying, the fine particles were sieved, then mixed with 2.7mg colloidal silicone dioxide and 2.0mg magnesium stearate. The fine particles were compressed to form tablets.

[0106] 3. Powder and capsules 5.0 mg of the active ingredient was sieved and mixed with 14.8 mg of lactose, 10.0 mg of polyvinylpyrrolidone, and 0.2 mg of magnesium stearate. The mixture was filled into No. 5 hard gelatin capsules using a suitable device.

[0107] 4. Injections An injection was prepared by dissolving 100 mg of the active ingredient, 180 mg of mannitol, and 26 mg of Na2HPO4 / H2O in 2974 mg of distilled water.

Claims

1. A compound represented by the following chemical formula 2, a stereoisomer thereof, a hydrate thereof, a solvate thereof, or a pharma- ceutically acceptable salt thereof: [Formula 1]

2. A pharmaceutical composition for preventing or treating a bone disease, comprising a compound represented by the following chemical formula 2, a stereoisomer thereof, a hydrate thereof, a solvate thereof, or a pharma- ceutical acceptable salt thereof as an active ingredient: [Case 2]

3. 3. The pharmaceutical composition for preventing or treating a bone disease according to claim 2, wherein the bone disease is selected from the group consisting of osteoporosis, bone fracture, rheumatoid arthritis, periodontitis, osteomalacia, osteopenia, bone atrophy, osteoarthritis, bone defect, osteolysis and osteonecrosis.

4. The pharmaceutical composition for preventing or treating a bone disease according to claim 2, wherein the compound represented by Chemical Formula 2 promotes differentiation of stem cells into osteoblasts.

5. The compound represented by Chemical Formula 2 increases the expression of a bone formation marker selected from the group consisting of runt-related transcription factor 2 (RUNX2), bone morphogenetic protein 2 (BMP2) and osteocalcin.

6. A food composition for preventing or improving bone diseases, comprising a compound represented by the following chemical formula 2 as an active ingredient: [C3]

7. The food composition for preventing or improving bone diseases according to claim 6, wherein the compound represented by Chemical Formula 2 promotes differentiation of stem cells into osteoblasts.

8. (a) reacting lappaconitine with an oxidizing agent; (b) reacting the result of (a) with an organic solvent in the presence of a base, to synthesize a compound represented by formula 2. [C4]

9. The oxidizing agent in (a) is iodobenzene diacetate (PhI(OAc) 2 , lead(II) acetate (Pb(CH 3 CO 2 ) 2 ), lead(II) acetate (Pb(CH 3 CO 2 ) 4 ), ozone and HIO 4 9. A method for synthesizing the compound of claim 8, wherein the compound is selected from the group consisting of:

10. 9. The method for synthesizing a compound according to claim 8, wherein the base in (b) is selected from the group consisting of sodium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate and potassium hydroxide.

11. The method for synthesizing a compound according to claim 8 , wherein the organic solvent (b) is an aliphatic alcohol or an alkoxy alcohol.

Citation Information

Patent Citations

  • Lappaconitine acetal derivative with antineoplastic activity and synthetic method thereof

    CN107540680A

  • Medicinal composition and its antalgic purpose

    CN1305811A

  • Lappaconitine aza-cinnamic acid derivatives with Anti-tumor activities and a method of preparing the same

    US20180093966A1

  • Agent exhibiting antiarrhythmic effect

    WO2017209653A1